Abstract
Importance The development and importance of ambulatory hypoxia in COVID-19 is unknown. The presence of ambulatory hypoxia may help risk-stratify hospitalized patients with COVID-19. If sufficient lead-time exists between development of ambulatory hypoxia and other outcome measures, interventions might be initiated earlier.
Objective To determine the association of ambulatory hypoxia with the eventual need for nasal cannula or advanced oxygenation therapies (defined as use of high flow nasal cannula, Bi-PAP, ventilator, or extracorporeal membrane oxygenation).
Design Retrospective, observational study of patients hospitalized with COVID-19 from March 1, 2020 to October 30, 2020.
Setting Ten hospitals in an integrated academic medical system (Northwestern Medicine) in the Chicagoland area.
Participants Adult patients (age ≥ 18) hospitalized for COVID-19 who had ambulatory oximetry measured.
Intervention(s) / Exposure(s) Ambulatory oximetry measurement.
Main outcomes and measures The association of ambulatory hypoxia with subsequent use of nasal cannula and advanced oxygen therapies and the time between ambulatory hypoxia and need for these oxygen therapies. Patients who had ambulatory oximetry measurements after use of nasal cannula or advanced oxygen therapies were excluded.
Results Of 531 patients with ambulatory oximetry measured, 132 (24.9%) had ambulatory hypoxia. Presence of ambulatory hypoxia was strongly associated with subsequent use of nasal cannula (OR 4.8, 95% CI 2.8 – 8.4) and advanced oxygen therapy (IRR 7.7, 95% CI 3.4 – 17.5). Ambulatory hypoxia measurement preceded nasal cannula use by a median 12.5 hours [IQR 3.25, 29.25] and advanced oxygenation therapies by 54 hours [IQR 25, 82].
Conclusion and Relevance Ambulatory hypoxia is associated with moderate to severe COVID-19. It may serve as an early, non-invasive physiologic marker for the likelihood of developing moderate to severe disease and help clinicians triage patients and initiate earlier interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received for this study.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Northwestern University IRB
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest: To the best of our knowledge, no conflict of interest, financial or other, exists for authors contributing to this report.
Author Involvement: All authors had access to the data, a role inwriting, reviewing, and approving the manuscript.
Data Availability
The data is available is available for review upon reasonable request